The added value of chlamydia screening between 2008-2010 in reaching young people in addition to chlamydia testing in regular care; an observational study by unknown
RESEARCH ARTICLE Open Access
The added value of chlamydia screening between
2008-2010 in reaching young people in addition to
chlamydia testing in regular care; an observational
study
Geneviève AFS van Liere1,2*, Nicole HTM Dukers-Muijrers1,2, Jan EAM van Bergen3, Hannelore M Götz4, Frans Stals5
and Christian JPA Hoebe1,2
Abstract
Background: Internet-based Chlamydia Screening Implementation (chlamydia screening programme) was introduced
in the Netherlands in 2008–2010 to detect and treat asymptomatic infections and to limit ongoing transmission
through annual testing and treatment of Chlamydia trachomatis in young people (16–29 years). This population-based
screening may be less effective when addressing individuals who are already covered by regular care, instead of
addressing a hidden key population without chlamydia testing experience in regular care. This study had two aims:
(1) to assess the rate and determinants of newly reached (i.e. not previously tested in 2006–2010) participants in the
chlamydia screening programme, and (2) to assess the chlamydia positivity in these newly reached participants.
Methods: This observational matching study included all chlamydia tests performed in subjects aged 16–29 years
in eastern South Limburg in the Netherlands (population 16–29 years:41,000) between 2006–2010. Testing was
conducted during the systematic chlamydia screening programme (2008–2010), at a sexually transmitted infections
clinic (STI clinic), by general practitioners (GPs), and by medical specialists as reported by the medical laboratory serving
the region. Data were matched between testing services on individual level. The study population included all
participants who were tested at least once for chlamydia by the chlamydia screening programme. Participants were
included at their first chlamydia screening participation.
Results: In the chlamydia screening programme, 80.7% (4298/5323) of participants were newly reached, others were
previously tested by the STI clinic (5.7%, n=304), GPs (6.2%, n=328), medical specialists (3.5%, n=187) or a combination
of providers (3.9%, n=206). Chlamydia prevalence was similar in newly reached participants (4.8%, 204/4298) and
participants previously tested (4.5%, 46/1025, P=0.82). Independent determinants for being a newly reached participant
were male gender (men OR 2.9; 95% CI 2.5-3.4) and young age <21 years (versus 25–29 years OR 1.8; 95% CI 1.5-2.2).
Conclusions: The majority of the chlamydia screening programme participants have not been tested by regular care,
and show similar chlamydia prevalence as those previously tested. Thereby population-based chlamydia screening
adds to the existing regular care by testing young individuals hidden to current regular care.
Keywords: Chlamydia screening, General practitioners, STI clinic, Medical specialists, Chlamydia, Testing, Newly reached
participants, Regular care, Young individuals, Hidden
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Background
Chlamydia is the most prevalent treatable sexually
transmitted infection worldwide and has major public
health consequences, especially in young women [1].
Early detection and treatment is warranted to limit the
spread of infection and to reduce sequelae in infected
individuals. A possible complication is pelvic inflammatory
disease, where Chlamydia trachomatis ascends to the
upper genital tract causing tubal factor infertility and
ectopic pregnancy. In the Netherlands the regular care
for testing and treatment of chlamydia is provided by
general practitioners (GPs), sexually transmitted infections
(STI) clinics and after referral by medical specialists
(mainly gynaecologists) [2]. Thus regular care providers
are GP’s, STI clinics and medical specialists. Systematic
population-based internet chlamydia screening was initi-
ated in 2008 and aimed to improve case finding to prevent
sequelae and to reduce population prevalence by annual
testing and treatment of people aged 16–29 years in three
regions in the Netherlands. The choice for targeting 16
to 29-year-olds in the additional chlamydia screening
programme was based on the highest burden of chla-
mydia infection among these young people [3,4]. After
a postal invitation, home sampling kits for urogenital
testing (urine or vaginal swab) could be requested through
a website. Treatment and partner notification were done
by the GP or at a STI clinic [5]. The rationale for the
chosen approach in the chlamydia screening programme
were based on existing evidence for screening pro-
grammes, costs, flexible communication, easy adaptation
of the screening in time and the possibility of easy expan-
sion to other geographic areas in the future [6]. Moreover,
acceptability of the screening method using internet was
high [7].
Keystones for an effective large-scale screening prog-
ramme are achieving adequate levels of participation [8]
and capturing substantial numbers of new (chlamydia
positive) participants in addition to regular care like STI
clinics and general practitioners (GPs). To understand and
interpret the outcome of chlamydia screening, knowing
who takes part in the chlamydia screening programme is
essential [9]. By assessing the totality of chlamydia testing
practices, it becomes clear whether the chlamydia screen-
ing programme reached persons already served by regular
care or a hidden key population without chlamydia testing
experience in regular care. Chlamydia screening would
become less effective when reaching those who were
already tested by regular care. Therefore chlamydia
screening should target this hidden key population to
prevent chlamydia sequelae in individuals and to diminish
further spread of chlamydia in the population additional
to the efforts in regular care. Publications assessing the
totality of chlamydia testing practices including additional
chlamydia screening in a programme are limited [10,11],
as such an assessment is frequently hampered by unavail-
ability of data or unmatchable data sources. Therefore the
rationale of this study was to bridge this gap and evaluate
this second keystone by using a near complete large data
collection of matched test data sources in the target region
for the chlamydia screening programme. This study had
two aims: (1) to assess the rate and determinants of newly
reached men and women aged 16–29 years in the chla-
mydia screening programme in eastern South Limburg,
and (2) to assess the chlamydia positivity in these newly
reached men and women.
Methods
Systematic chlamydia screening in the Netherlands
The Dutch chlamydia screening programme used
systematic-population-based internet chlamydia screen-
ing in three regions of the Netherlands, including the
eastern South Limburg study area. The intervention
was implemented by means of a stepped wedge design,
with sequential roll out to geographical clusters of
potential participants in a randomly determined order
over time so that, by the end of the three year study
period, each cluster had been invited at least once. The
stepped wedge design was chosen to be able to evaluate
participation and effectiveness over several rounds of
screening. In three screening rounds from 2008–2010,
all men and women aged 16–29 years who were listed in
the study area’s municipal population register (n = 41,000,
2010) were sent an invitation letter [5]. In our study area
South Limburg, eligibility for chlamydia testing within
the chlamydia screening programme depended on an
individual’s chlamydia risk score. This risk score was
based on answers to an eight-item risk questionnaire
(i.e. age, place of residence, education level, condom
use at last intercourse, number of lifetime sex contacts,
ethnic background, having a new sexual partner in the
last 6 months and symptoms) [12]. When a person was
eligible, home sampling kits for urogenital testing could
be requested through a website (www.chlamydiatest.nl).
Chlamydia screening participants could provide add-
itional data via an optional electronic general questionnaire
(hereafter questionnaire).
Study design; data collection and matching
Three data sources were used for all the men and
women aged 16–29 years who were tested for chlamydia
in the study area between 2006 and 2010: the chlamydia
screening programme, an STI clinic, and the medical
laboratory [13]. Data from GPs and medical specialists
(mainly gynaecologists) were obtained from the regional
medical microbiology laboratory covering the study area
(>95%). Data from the STI clinic were retrieved from
our public health STI clinic’s medical records comprising
confirmed test results. The basis for data matching was
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the municipal population register, which included men
and women aged 16–29 years who were invited for and
tested in the chlamydia screening programme. Data from
GPs and medical specialists were uniquely matched to the
register on personal level by part of the last name, month
of birth, year of birth, sex, and postal code. Part of the
test records had identical part of the last name, month
of birth, year of birth, sex, and postal code. These
records were considered to belong to the same individual,
and were matched to the identical municipal population
register record. For chlamydia screening participants, a
ranking order was assigned to all matched records from
GPs and medical specialists (medical laboratory) for
sensitivity analyses. Data from the STI clinic were all
matched uniquely to the register based on the whole
name and date of birth (Figure 1).
Study population
The study population included all participants who were
tested at least once for chlamydia by the chlamydia
screening programme. Participants were included at their
first chlamydia screening participation. Data on sex, age,
and test result were available for all participants, data
on same-sex behaviour, symptoms and number of sex
partners in the past six months was only available for
participants who filled in questionnaire. Variables used
for analyses were sex, age (≤21, 22–24, 25–29 years
(reference), based on tertiles), test result, nationality
(Western vs. non-Western), same-sex behaviour (men
who have sex with men, heterosexual men and women
(reference)), symptoms, and number of sex partners in
the past six months (1, 2, ≥3, based on tertiles).
Chlamydia trachomatis diagnosis
Specimens tested by the chlamydia screening programme
and at the STI clinic came from mostly self-collected
vaginal swabs and urine. GPs and medical specialists
used mostly clinician-collected urethral and cervical
swabs. The STI clinic, GPs, and medical specialists used
SDA and PCR for Chlamydia trachomatis testing (Becton
Dickinson ProbeTec ET system, Maryland, USA and from
6-1-2010 Abbott M2000, Illinois, USA). The chlamydia
screening programme used PCR (Roche Cobas Taqman,
California, USA). All tests were performed according to
the manufacturers’ protocols.
Analysis
At the first chlamydia screening participation, we assessed
whether participants were previously tested by one or
more regular care providers between 2006–2010 based
on matched data. Participants who were not previously
tested were defined as ‘newly reached participant’. The
proportion of positive chlamydia tests was compared
between newly reached participants and previously tested
Municipal population register 
N=41.000 persons
Matching
1 on 1 100%
Matching
1 on 1 100%
Matching
1 on 1 87.6%
1 on 2 10.7% 
1 on 3 1.6%
















Figure 1 Flow diagram of the data matching and study procedures. Data from the STI clinic, the chlamydia screening programme, GPs and the
hospital were matched at individual level to the municipal population register. Data from the STI clinic and the chlamydia screening programme were
matched uniquely. Data from GPs and hospital were matched by probabilistic algorithmic matching. The study population included all participants
who were screened at least once for chlamydia (n = 5395).
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participants using a Chi square test; adjusting for age
and gender did not change the results. Logistic regression
analysis was performed: being a newly reached participant
was used as the outcome to assess the association with
the determinants age, sex, nationality and test result.
To assess the association between newly reached par-
ticipant and determinants from the questionnaire, the
second analysis was restricted to participants with a
questionnaire. Assessed determinants included age, sex,
nationality, sexual preference, symptoms, number of
sex partners in the past six months and test result. To
test for selection bias, age, sex, nationality, test result
and newly reached participant were compared between
participants with and without questionnaire using Chi
square test. Independent determinants were assessed by
multivariable analyses using stepwise backward selec-
tion. Interactions terms were added in the multivariable
model but none were statistically significant and they
were not included in the final model. All analyses were
adjusted for year of invitation for the chlamydia screen-
ing. A P value <0.05 was considered to be statistically
significant. Analyses were performed using the SPSS
package version 20 (IBM Inc. Somers, New York, USA).
Ethics statement
Participants, including minors (16–18 years-old), provided
written consent to participate in this study, including
consent for further research. No written consent was
obtained from next of kin, caretakers, or guardians on
behalf of the minors enrolled in the study. The Medical
Ethics Committee of the VU University Amsterdam
(Identification number 2007/239) approved the chla-
mydia screening trial. The Medical Ethics Committee
of Maastricht University (Identification number 12-4-042)




The STI clinic database comprised 4821 young people
(16–29 years), the GP and hospital database comprised
16.717 young people. In total 41.000 young people were
invited for chlamydia screening, 5395 participated at
least once (13.2%). Participants who were 16 years old at
the first chlamydia screening (n = 72) were excluded
from analysis because there were no previous testing
data available from regular care providers. The study
population comprised 5323 participants (participation
13.0%). Of all test records matched from GPs and medical
specialists with the chlamydia screening participants in the
municipal population register (n = 1287), 87.6% (n = 1127)
were matched uniquely, 10.7% (n = 138) were matched 1
on 2, 1.6% (n = 21) were matched 1 on 3, and 0.1% (n = 1)
was matched 1 on 4. Data from the STI clinic were all
uniquely (1 on 1) matched based on first name, last name,
date of birth, sex, and postal code (n = 422). In total, 90.6%
(1549/1709) of data were uniquely matched (1 on 1)
(Figure 1).
Study population
The largest proportion of participants consisted of partici-
pants 25–29 years of age, followed by participants of 22–
24 years of age. Two thirds of participants were women,
and the majority had Western nationality (>95%). In total,
59.1% (n = 3162) of participants filled in the questionnaire.
Participants without questionnaire were older, more often
men, more often had non-Western nationality and had
lower chlamydia prevalence compared to participants with
questionnaire (Table 1).
Newly reached participants
In the chlamydia screening programme, 80.7% (4298/
5323) of participants were newly reached (not previously
tested). The other participants had been tested previously
at least once: 5.7% (304/5323) by the STI clinic, 6.2%
(328/5323) by GPs, 3.5% (187/5323) by medical specialists,
and 3.9% (206/5323) by a combination of providers. The
proportion of newly reached participants was comparable
in participants with and without questionnaire (Table 1).
Of all previous tests, 2.7% (n = 28) were tested within
3 months before chlamydia screening participation.
Determinants newly reached participants
In multivariable analyses, independent determinants for
a newly reached participant were male gender and young
age. Nationality and test result were not associated. In
restricted analyses including questionnaire data, further
identified independent determinants for newly reached
participants were young age, having had 1 or 2 sex part-
ners (compared to 3 sex partners), being a man who had
sex with men (MSM), and being a heterosexual man
(compared to women). Sex, symptoms, or test result (see
section below) were not associated (Table 2).
Proportion chlamydia positive tests
The proportion of chlamydia positive tests was compar-
able in newly reached participants (4.8%, 204/4298)
versus participants previously tested at an STI clinic
(3.6%, 11/304), by GPs (5.2%, 17/328), by medical special-
ists (3.7%, 7/187), or by a combination of providers (5.3%,
11/206) (P = 0.82). Overall, the proportion chlamydia
positive tests was highest for the young participants
(<21 years, 5.7%; age 22 to 24 years, 5.4%; age 25–29
years, 3.3%; P = 0.001).
Discussion
This study assessed the totality of chlamydia tests in one
geographic region by matching all chlamydia testing data
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to the municipal population register, including testing by
systematic population-based chlamydia screening, the
STI clinic, GPs and medical specialists. The chlamydia
screening programme predominantly addressed new,
previously untested, young participants who were not
reached by regular care (81%) and who had similar uro-
genital chlamydia prevalence as participants previously
tested elsewhere (4.8% vs. 4.5%). Therefore, we can con-
clude that the chlamydia screening programme adds to
the existing regular care by revealing a so-far hidden
population.
In this study, all chlamydia tests were collected: by
regular care (GPs, STI clinic and medical specialists)
and by intervention (chlamydia screening). There was
no specific promotion of chlamydia testing during the
chlamydia screening period that could have biased our
results [5]. Previous studies also matched data from
sexually transmitted infections/medical conditions diag-
nosed in several care settings to assess the proportion
positives [11], births [14], ectopic pregnancies [14,15],
and reproductive capacity [15] after a chlamydia test.
Our study adds to these previous studies by using the
municipal population register which covers the entire
population young people in one geographic region. This
enabled assessing the totality of chlamydia testing, which
was previously unknown [10].
Previous studies analysed participants in the English
National Chlamydia Screening Programme (NCSP) and
part of the Dutch systematic chlamydia screening
programme. The NCSP is an opportunistic screening
programme that offers chlamydia screening to eligible,
sexually active individuals younger than 25 years when
they attend consultations at specified health care, or
other, settings [16]. Socio-demographic factors associated
with participation in England were female gender and
younger age [17]. Moreover, coverage was higher in
deprived populations [18]. In the urbanised regions in
the Netherlands, excluding this South Limburg study
area, these factors were female gender and older age
[8]. Separate analyses of South Limburg data gave simi-
lar results: female gender and older age were associated
with participation (data not shown). In this study,
newly reached participants turned out to be more often
men, young (<21 years), and had had fewer sex partners
compared to participants previously tested by regular
care. This is important since men are usually harder to
reach in screening programmes [16]. A possible explanation
for this could be that men prefer testing in non-clinical
settings such as postal testing kits and internet based
screening [19]. In England only 15% of young men were
tested for chlamydia last year in contrast to 35% of young
women [20]. A qualitative study examining the barriers
and facilitators of offering chlamydia testing in general
practitioners (GPs) and practice nurses revealed that
women have more consultations and it is easier to raise
sexual health issues within the type of consultations
women are seeking. Moreover, awkwardness and embar-
rassment were reported in raising chlamydia screening
with men [21]. Another study found that GPs are reluc-
tant to test young people for chlamydia in absence of
urogenital symptoms [22]. Altogether, internet based
screening could be helpful to stimulate especially young
men [23]. New e-health strategies could provide more
insight in the sexual and testing behaviour of young
people [24].
Younger age is known to be associated with testing
positive for chlamydia [8,20], this makes young people a
target group to reach in chlamydia screening. New
Table 1 Characteristics of chlamydia screening programme participants without and with questionnaire
Variables Participants without questionnaire
N = 2161 % (N)
Participants with questionnaire
N = 3162 % (N)
Total
N = 5323 % (N)
Age
≤ 21 24.2 (523) 28.7 (906)* 26.8 (1429)
22-24 36.1 (781) 34.2 (1081) 35.0 (1862)
25-29 39.7 (857) 37.2 (1175) 38.2 (2032)
Sex
Men 42.5 (919) 29.1 (919)* 34.5 (1838)
Women 57.5 (1242) 70.9 (2243) 65.5 (3485)
Nationality
Non- Western 3.8 (81) 2.0 (64)* 2.7 (145)
Chlamydia
Yes 2.9 (63) 5.9 (181)* 4.7 (250)
Newly reached participant
Yes 80.8 (1746) 80.7 (2552) 80.7 (4298)
*P < 0.01.
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participants had fewer sex partners, an explanation could
be that people with more sex partners are more likely to
attend STI clinics [25].
The chlamydia prevalence of newly reached participants
was comparable to that of participants previously tested by
regular care, and groups tested in other healthcare settings
such as the STD clinic [26] and GPs [27]. This indicates
that the chlamydia screening programme complements
regular care in detecting chlamydia positives.
Sex was associated with being a newly reached partici-
pant in overall analyses, but not in additional analyses on
questionnaire data. A possible explanation could be that a
Table 2 Characteristics of newly reached participants and previously tested participants
Variables Newly reached participants
N = 4298 % (N)
Previously tested







≤ 21 28.7 (1233) 19.1 (196) 1.63 (1.4-2.0) 1.8 (1.5-2.2) <0.001
22-24 33.8 (1451) 40.1 (411) 0.9 (0.8-1.1) 1.0 (0.8-1.1) 0.56
25-29 37.6 (1614) 40.8 (418) 1 1
Sex
Men 38.3 (1646) 18.7 (192) 2.7 (2.3-3.2) 2.9 (2.5-3.4) <0.001
Women 61.7 (2652) 81.3 (833) 1 1
Chlamydia
Yes 4.8 (204) 4.5 (46) 1.1 (0.8-1.5) ns
No 1
Nationality
Non-Western 2.6 (111) 3.3 (34) 0.8 (0.5-1.2)
Western 96.7 (990) 97.4 (4159) 1 ns
Restricted analyses
Age
≤ 21 30.7 (783) 20.2 (123) 1.7 (1.4-2.2) 1.7 (1.3-2.2) <0.001
22-24 33.0 (842) 39.2 (239) 0.9 (0.8-1.2) 1.0 (0.8-1.2) 0.78
25-29 36.3 (927) 40.7 (248) 1 1 1
Sex
Men 32.4 (827) 15.1 (92) 2.7 (2.1-3.4) ns
Women 67.6 (1725) 84.9 (518) 1
Chlamydia
Yes 5.9 (150) 6.1 (37) 1.0 (0.7-1.4) ns
No 94.1 (2402) 93.9 (573) 1
Sexual preference
Men who have sex with men 1.7 (39) 0.9 (5) 2.3 (0.9-5.9) 4.0 (1.6-10.6) <0.01
Heterosexual men 30.4 (715) 13.8 (77) 2.8 (2.2-3.6) 3.3 (2.6-4.3) <0.001
Women 67.9 (1598) 85.3 (477) 1 1
Sex partners
1 73.3 (1713) 63.8 (353) 1.8 (1.4-2.4) 2.6 (1.9-3.4) <0.001
2 15.9 (371) 19.2 (106) 1.3 (0.9-1.8) 1.7 (1.2-2.4) <0.01
≥3 10.8 (253) 17.0 (94) 1 1
Symptoms
Yes 2.4 (62) 3.0 (18) 1.3 (0.8-2.1) ns
No 97.6 (2490) 97.0 (592) 1
Crude percentages and independent determinants for being a newly reached participant in univariate and multivariable analyses. Analyses were corrected for
age, sex, and year of invitation. Restricted analyses were corrected for age, sexual preference, number of sex partners, and year of invitation.
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smaller proportion of men filled in the questionnaire
compared to women. Being MSM was associated with
being a newly reached participant, although this key
population needs additional extra genital testing to fully
address their risk behaviour [26]. Chlamydia testing was
limited to urogenital site, which might underestimate the
true burden of chlamydia as other studies showed that
prevalence of anorectal chlamydia is substantial in both
MSM and women [26,28,29].
This study has several limitations. First, it consists of
not 100% uniquely matched data but 91%. The last 9%
was matched using test records with identical markers
from GPs and medical specialists. This slight inaccuracy
might have introduced some bias and could lead to an
underestimation of the proportion new participants. How-
ever, we expect this bias to be negligible as a sensitivity
analysis on uniquely matched data revealed similar results.
Unfortunately, data from care providers were only avail-
able for a restricted timeframe (2006–2010), limiting our
results. It is possible that newly reached participants could
have visited regular care before 2006.
Another limitation is that additional data on sexual
behaviour was only available for the group that filled in
extra self-administered questionnaires, which could
lead to bias for the restricted data analysis. However,
odds ratios for age were similar for the main analysis
and the restricted data analysis (see Table 1), indicating
that bias was unlikely.
The study area itself was another limitation. The eastern
South Limburg region in the Netherlands is the first study
area with sufficient and matchable data sources that can
be used to assess the totality of chlamydia testing. How-
ever, this region is partly rural and it is unknown where
data can be extrapolated to other participation regions
that are more urban, such as Amsterdam and Rotterdam.
We have to acknowledge that the generalizability of our
results might be confined as screening programmes in
different countries vary widely because of differences in
recruitment methods, sample frames and participation
rates. Moreover, not all persons in eastern South Limburg
requesting chlamydia testing through the website were
eligible due to the individuals’ chlamydia risk score. This
may have led to higher positivity rates compared to
systematic screening [12]. In a postal non-response study,
no indications were found that participation in the screen-
ing was hampered by limited access to the internet. Non
response to the screening was largely based on percep-
tions of individual risk [6].
Conclusions
This study contributes to understanding the impact of
chlamydia screening in reaching previously untested
young people. In this study, chlamydia screening reached
a hidden key population of young men and women who
had never been tested before and who as a group showed
a prevalence of chlamydia comparable to clinical settings.
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